The role of the primitive marker CD133 in CD34-negative acute myeloid leukemia for the detection of leukemia stem cells

Tom Reuvekamp; Luca L. G. Janssen; Lok Lam Ngai; Jannemieke Carbaat-Ham; Daphne den Hartog; Willemijn J. Scholten; Angele Kelder; Diana Hanekamp; Eliza Wensink; Noortje van Gils; Patrycja Gradowska; Bob Lowenberg; Gert J. Ossenkoppele; Arjan A. van de Loosdrecht; Theresia M. Westers; Linda Smit; Costa Bachas; Jacqueline Cloos

doi:10.1002/cyto.b.22201

The role of the primitive marker CD133 in CD34-negative acute myeloid leukemia for the detection of leukemia stem cells

Tom Reuvekamp, Luca L. G. Janssen, Lok Lam Ngai, Jannemieke Carbaat-Ham, Daphne den Hartog, Willemijn J. Scholten, Angele Kelder, Diana Hanekamp, Eliza Wensink, Noortje van Gils, Patrycja Gradowska, Bob Lowenberg, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht, Theresia M. Westers, Linda Smit, Costa Bachas, Jacqueline Cloos

Hematology

Research output: Contribution to journal › Article › Academic › peer-review

23 Downloads (Pure)

Abstract

The most important reason for dismal outcomes in acute myeloid leukemia (AML) is the development of relapse. Leukemia stem cells (LSCs) are hypothesized to initiate relapse, and high CD34+CD38− LSC load is associated with poor prognosis. In 10% of AML patients, CD34 is not or is low expressed on the leukemic cells (<1%), and CD34+CD38− LSCs are absent. These patients are classified as CD34-negative. We aimed to determine whether the primitive marker CD133 can detect LSCs in CD34-negative AML. We retrospectively quantified 148 CD34-negative patients for proportions of CD34−CD133+ and CD133+CD38− cell fractions in the diagnostic samples of CD34-negative patients in the HOVON102 and HOVON132 trials. No prognostic difference was found between patients with high or low proportions of CD34−CD133+, which is found to be aberrantly expressed in AML. A high level of CD133+CD38− cells was not associated with poor overall survival, and expression in AML was similar to normal bone marrow. To conclude, CD133 is useful as an additional primitive marker for the detection of leukemic blast cells in CD34-negative AML. However, CD133+CD38 alone is not suitable for the detection of LSCs at diagnosis.

Original language	English
Number of pages	12
Journal	Cytometry Part B-Clinical Cytometry
Early online date	23 Aug 2024
DOIs	https://doi.org/10.1002/cyto.b.22201
Publication status	E-pub ahead of print - 23 Aug 2024

Bibliographical note

Publisher Copyright:
© 2024 The Author(s). Cytometry Part B: Clinical Cytometry published by Wiley Periodicals LLC on behalf of International Clinical Cytometry Society.

Access to Document

10.1002/cyto.b.22201Licence: CC BY-NC

Cytometry Part B Clinical - 2024 - Reuvekamp - The role of the primitive marker CD133 in CD34‐negative acute myeloidFinal published version, 3.34 MBLicence: CC BY-NC

Cite this

Reuvekamp, T., Janssen, L. L. G., Ngai, L. L., Carbaat-Ham, J., den Hartog, D., Scholten, W. J., Kelder, A., Hanekamp, D., Wensink, E., van Gils, N., Gradowska, P., Lowenberg, B., Ossenkoppele, G. J., van de Loosdrecht, A. A., Westers, T. M., Smit, L., Bachas, C., & Cloos, J. (2024). The role of the primitive marker CD133 in CD34-negative acute myeloid leukemia for the detection of leukemia stem cells. Cytometry Part B-Clinical Cytometry. Advance online publication. https://doi.org/10.1002/cyto.b.22201

@article{8ac71097eb404ac986438c3ceb5d810e,

title = "The role of the primitive marker CD133 in CD34-negative acute myeloid leukemia for the detection of leukemia stem cells",

abstract = "The most important reason for dismal outcomes in acute myeloid leukemia (AML) is the development of relapse. Leukemia stem cells (LSCs) are hypothesized to initiate relapse, and high CD34+CD38− LSC load is associated with poor prognosis. In 10% of AML patients, CD34 is not or is low expressed on the leukemic cells (<1%), and CD34+CD38− LSCs are absent. These patients are classified as CD34-negative. We aimed to determine whether the primitive marker CD133 can detect LSCs in CD34-negative AML. We retrospectively quantified 148 CD34-negative patients for proportions of CD34−CD133+ and CD133+CD38− cell fractions in the diagnostic samples of CD34-negative patients in the HOVON102 and HOVON132 trials. No prognostic difference was found between patients with high or low proportions of CD34−CD133+, which is found to be aberrantly expressed in AML. A high level of CD133+CD38− cells was not associated with poor overall survival, and expression in AML was similar to normal bone marrow. To conclude, CD133 is useful as an additional primitive marker for the detection of leukemic blast cells in CD34-negative AML. However, CD133+CD38 alone is not suitable for the detection of LSCs at diagnosis.",

author = "Tom Reuvekamp and Janssen, {Luca L. G.} and Ngai, {Lok Lam} and Jannemieke Carbaat-Ham and {den Hartog}, Daphne and Scholten, {Willemijn J.} and Angele Kelder and Diana Hanekamp and Eliza Wensink and {van Gils}, Noortje and Patrycja Gradowska and Bob Lowenberg and Ossenkoppele, {Gert J.} and {van de Loosdrecht}, {Arjan A.} and Westers, {Theresia M.} and Linda Smit and Costa Bachas and Jacqueline Cloos",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s). Cytometry Part B: Clinical Cytometry published by Wiley Periodicals LLC on behalf of International Clinical Cytometry Society.",

year = "2024",

month = aug,

day = "23",

doi = "10.1002/cyto.b.22201",

language = "English",

journal = "Cytometry Part B-Clinical Cytometry",

issn = "1552-4949",

publisher = "Wiley-Liss Inc.",

}

Reuvekamp, T, Janssen, LLG, Ngai, LL, Carbaat-Ham, J, den Hartog, D, Scholten, WJ, Kelder, A, Hanekamp, D, Wensink, E, van Gils, N, Gradowska, P , Lowenberg, B, Ossenkoppele, GJ, van de Loosdrecht, AA, Westers, TM, Smit, L, Bachas, C & Cloos, J 2024, 'The role of the primitive marker CD133 in CD34-negative acute myeloid leukemia for the detection of leukemia stem cells', Cytometry Part B-Clinical Cytometry. https://doi.org/10.1002/cyto.b.22201

TY - JOUR

T1 - The role of the primitive marker CD133 in CD34-negative acute myeloid leukemia for the detection of leukemia stem cells

AU - Reuvekamp, Tom

AU - Janssen, Luca L. G.

AU - Ngai, Lok Lam

AU - Carbaat-Ham, Jannemieke

AU - den Hartog, Daphne

AU - Scholten, Willemijn J.

AU - Kelder, Angele

AU - Hanekamp, Diana

AU - Wensink, Eliza

AU - van Gils, Noortje

AU - Gradowska, Patrycja

AU - Lowenberg, Bob

AU - Ossenkoppele, Gert J.

AU - van de Loosdrecht, Arjan A.

AU - Westers, Theresia M.

AU - Smit, Linda

AU - Bachas, Costa

AU - Cloos, Jacqueline

PY - 2024/8/23

Y1 - 2024/8/23

N2 - The most important reason for dismal outcomes in acute myeloid leukemia (AML) is the development of relapse. Leukemia stem cells (LSCs) are hypothesized to initiate relapse, and high CD34+CD38− LSC load is associated with poor prognosis. In 10% of AML patients, CD34 is not or is low expressed on the leukemic cells (<1%), and CD34+CD38− LSCs are absent. These patients are classified as CD34-negative. We aimed to determine whether the primitive marker CD133 can detect LSCs in CD34-negative AML. We retrospectively quantified 148 CD34-negative patients for proportions of CD34−CD133+ and CD133+CD38− cell fractions in the diagnostic samples of CD34-negative patients in the HOVON102 and HOVON132 trials. No prognostic difference was found between patients with high or low proportions of CD34−CD133+, which is found to be aberrantly expressed in AML. A high level of CD133+CD38− cells was not associated with poor overall survival, and expression in AML was similar to normal bone marrow. To conclude, CD133 is useful as an additional primitive marker for the detection of leukemic blast cells in CD34-negative AML. However, CD133+CD38 alone is not suitable for the detection of LSCs at diagnosis.

AB - The most important reason for dismal outcomes in acute myeloid leukemia (AML) is the development of relapse. Leukemia stem cells (LSCs) are hypothesized to initiate relapse, and high CD34+CD38− LSC load is associated with poor prognosis. In 10% of AML patients, CD34 is not or is low expressed on the leukemic cells (<1%), and CD34+CD38− LSCs are absent. These patients are classified as CD34-negative. We aimed to determine whether the primitive marker CD133 can detect LSCs in CD34-negative AML. We retrospectively quantified 148 CD34-negative patients for proportions of CD34−CD133+ and CD133+CD38− cell fractions in the diagnostic samples of CD34-negative patients in the HOVON102 and HOVON132 trials. No prognostic difference was found between patients with high or low proportions of CD34−CD133+, which is found to be aberrantly expressed in AML. A high level of CD133+CD38− cells was not associated with poor overall survival, and expression in AML was similar to normal bone marrow. To conclude, CD133 is useful as an additional primitive marker for the detection of leukemic blast cells in CD34-negative AML. However, CD133+CD38 alone is not suitable for the detection of LSCs at diagnosis.

UR - http://www.scopus.com/inward/record.url?scp=85201974984&partnerID=8YFLogxK

U2 - 10.1002/cyto.b.22201

DO - 10.1002/cyto.b.22201

M3 - Article

C2 - 39177948

SN - 1552-4949

JO - Cytometry Part B-Clinical Cytometry

JF - Cytometry Part B-Clinical Cytometry

ER -

The role of the primitive marker CD133 in CD34-negative acute myeloid leukemia for the detection of leukemia stem cells

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this